These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17227621)

  • 1. Enteric-coated solid dosage forms containing sodium bicarbonate as a drug substance: an exception from the rule?
    Breitkreutz J; Gan TG; Schneider B; Kalisch P
    J Pharm Pharmacol; 2007 Jan; 59(1):59-65. PubMed ID: 17227621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
    Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
    Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release.
    Varum FJ; Merchant HA; Goyanes A; Assi P; Zboranová V; Basit AW
    Int J Pharm; 2014 Jul; 468(1-2):172-7. PubMed ID: 24727141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products.
    Liu F; Merchant HA; Kulkarni RP; Alkademi M; Basit AW
    Eur J Pharm Biopharm; 2011 May; 78(1):151-7. PubMed ID: 21255647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation of intelligent tablets with an antacid effect.
    Bajdik J; Korbely A; Pintye-Hódi K
    Pharm Dev Technol; 2009; 14(5):471-5. PubMed ID: 19552554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dissolution properties of 2 enteric-coated formulations containing mycophenolate sodium: Myfortic vs Femulan.
    Esquivel A; González-Ramírez R; Alberú J; Gracida C; Medeiros M; Castañeda-Hernández G
    Transplant Proc; 2010; 42(1):353-6. PubMed ID: 20172348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Resistance and disintegration behavior of gastric juice-resistant drug products. 3. Pharmaceutical-technological and analytical studies of gastric juice-resistant commercial preparations].
    Thoma K; Heckenmüller H; Oschmann R
    Pharmazie; 1987 Dec; 42(12):832-6. PubMed ID: 3444845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the gastrointestinal behaviour of modified-release products: utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers.
    Merchant HA; Goyanes A; Parashar N; Basit AW
    Int J Pharm; 2014 Nov; 475(1-2):585-91. PubMed ID: 25195730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissolution evaluation of marketed tetracyclines solid oral dosage forms.
    Yamamoto CH; Pinto Tde J; Alves MS
    Boll Chim Farm; 2000; 139(2):81-4. PubMed ID: 10920533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of sensor elements to control drug release from capsular drug delivery systems.
    Gröning R; Danco I; Müller RS
    Int J Pharm; 2007 Aug; 340(1-2):61-4. PubMed ID: 17462841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The bioavailability of sulpiride taken as a film-coated tablet with sodium bicarbonate, cimetidine, natural orange juice or hydrochloric acid.
    Shinkuma D; Hamaguchi T; Kobayashi M; Yamanaka Y; Mizuno N
    Int J Clin Pharmacol Ther Toxicol; 1989 Oct; 27(10):499-502. PubMed ID: 2555311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of product formulation on in vitro activity of pancreatic enzymes.
    Dressman JB; Shtohryn LV; Diokno D
    Am J Hosp Pharm; 1985 Nov; 42(11):2502-6. PubMed ID: 4073069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro dissolution of oral modified-release tablets and capsules in ethanolic media.
    Smith AP; Moore TW; Westenberger BJ; Doub WH
    Int J Pharm; 2010 Oct; 398(1-2):93-6. PubMed ID: 20667505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets.
    Breier AR; Paim CS; Steppe M; Schapoval EE
    J Pharm Pharm Sci; 2005 Aug; 8(2):289-98. PubMed ID: 16124939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems.
    Fadda HM; Merchant HA; Arafat BT; Basit AW
    Int J Pharm; 2009 Dec; 382(1-2):56-60. PubMed ID: 19666093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buoyant sustained release tablets based on chitosan.
    Inouye K; Machida Y; Sannan T; Nagai T
    Drug Des Deliv; 1988 Feb; 2(3):165-75. PubMed ID: 2855572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.